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Background: Traditionally, the treatment of a thrombosed dialysis access in
hemodialysis patients in Korea has been primarily performed by vascular surgeons
and interventional radiologists. The objective of this study was to evaluate the
outcome of percutaneous thrombectomy procedures performed by an interven-
tional nephrologist.
Methods: From October 2010 to May 2014, 75 consecutive percutaneous thrombec-
tomies were performed on 42 patients treated with maintenance hemodialysis. All
percutaneous thrombectomy procedures were performed by an interventional nephrol-
ogist in a single hospital in Jeju, Korea. The thrombosed arteriovenous graft and
arteriovenous ﬁstula were declotted by thromboaspiration mechanical thrombectomy
or pharmacomechanical thrombolysis. Kaplan–Meier survival analysis was performed
to analyze the primary and secondary patency after the initial successful thrombectomy.
Success and complication rates were identiﬁed and compared with the recommenda-
tions of the Kidney Disease Dialysis Outcomes Quality Initiative (KDOQI) guideline.
Results: The overall clinical success rate was 89.3% (67/75). In the successful cases, the
postintervention primary (unassisted) patency rates at 30 days, 90 days, and 180 days
were 79.9%, 56.6%, and 25.6%, respectively. The secondary patency rates at 30 days, 90
days, and 180 days were 92.2%, 85.7%, and 83.7%, respectively. There were no major
complications, and all complications were treated successfully during the procedure.
Conclusion: The clinical success rate and primary patency rate at 3 months exceeded
the recommendations of the KDOQI guideline, and were comparable to that of other
reports. Percutaneous thrombectomy by an interventional nephrologist was safe and
effective.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In Korea,452,000 patients currently undergo maintenance
hemodialysis as a renal replacement therapy, and the proportionn Society of Nephrology. Publi
c-nd/4.0/).
ology, Hanmaeum Hospi-
orea.of elderly and diabetic patients is growing rapidly [1]. Along with
the rapid increase of the hemodialysis population and the
hemodialysis life expectancy, the incidence of vascular access
complications has also grown at an exponential rate. As such,
maintaining a durable dialysis access has become even more
challenging. Above all, dialysis access thrombosis remains a
nightmare to hemodialysis patients and the dialysis staff. The
necessity for a temporary hemodialysis catheter owing to an
occluded vascular access can cause much apprehension, pain,shed by Elsevier. This is an open access article under the CC BY-NC-ND
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As such, thrombosis of arteriovenous ﬁstula (AVF) and arterio-
venous graft (AVG) should be treated as soon as possible without
unnecessary delay and within 48 hours, prior to the next dialysis
session. Early declotting allows for immediate use of the access
without the need for a central venous catheter [2]. At the same
time, the current Kidney Disease Dialysis Outcomes Quality
Initiative (KDOQI) clinical practice guidelines emphasize that
each institution should monitor the outcome of the treatment
on the basis of graft patency following percutaneous thrombect-
omy [3].
Traditionally, the treatment of thrombosed dialysis access in
hemodialysis patients in Korea has been performed by vascular
surgeons and interventional radiologists. However, interven-
tional nephrologists are quickly developing into specialists that
actively perform dialysis access interventional procedures, and
percutaneous thrombectomy by interventional nephrologists
has become popular worldwide in recent years.
In the current study, we retrospectively reviewed percuta-
neous thrombectomy by an interventional nephrologist in a
single hospital and report the outcome according to the
criteria from the Society of Interventional Radiology (SIR) [4]
and the recommended criteria in the KDOQI guidelines.Methods
Patient population
Seventy-ﬁve percutaneous thrombectomy procedures were
performed by an interventional nephrologist in a single
hospital in Jeju, Korea. All referred patients from other dialysis
centers were sent back to the referring doctors after successful
treatment, and successful hemodialysis was conﬁrmed by
telephone survey to both the patients and dialysis centers.
In this study, access thrombosis was deﬁned as a clinical
status that meets all of the following criteria: a totally
occluded access without thrill and bruit as seen by physical
examination; with thrombus, as conﬁrmed by ultrasono-
graphic examination; and an accesses inability to be used for
hemodialysis treatment. Patients were excluded from percu-
taneous thrombectomy if they had an infected vascular access
or severe contrast allergies. There were three cases excluded
owing to infected access during this study.
We retrospectively reviewed an existing database from our
angiographic unit of consecutive percutaneous thrombectomy
procedures for thrombosed arteriovenous ﬁstulas and grafts.
This single-center retrospective study was approved by the
Korea National Institute for Bioethics Policy (IRB number, P01-
201408-RS-01-00), and informed consent was obtained prior
to the thrombectomy procedures.
Procedure technique
Devices
In all cases, we performed duplex Doppler ultrasound
examinations with LOGIQ P5 (GE Healthcare, Salt Lake City,
UT, USA) prior to the declotting procedures. All percutaneous
thrombectomy procedures were performed in an angiography
suite equipped with an INNOVA 3100 Angiographic Imaging
System (GE Healthcare). We used devices, such as a noncom-
pliant balloon catheter (Cook, Bloominton, IN, USA) for throm-
bus maceration and angioplasty, a 5F Fogarty thrombectomyballoon catheter (Edwards Lifesciences, Irvine, CA, USA) for
arterial plug removal, and a Desilets–Hoffman sheath (Cook)
for thrombus aspiration.
Declotting procedures
Declotting procedures for AVG thrombosis were performed
using either a crossed-catheter technique [5] or an apex
puncture technique [6].
In the loop arteriovenous graft, the apex puncture techni-
que was performed for thromboaspiration using a 7F Desilets–
Hoffman sheath. The apex of the loop graft was punctured
with a 21G micropuncture needle set (Cook), and a 7F
Desilets–Hoffman sheath was inserted toward the venous
limb. If a central vein stenosis was present, percutaneous
transluminal balloon angioplasty (PTA) was performed prior
to declotting. A thromboaspiration mechanical thrombectomy,
using a Desilets–Hoffman sheath, was performed to remove
the clot from the venous limb of the graft. Any signiﬁcant
(450%) stenoses in the outﬂow vein and venous anastomosis
were treated by using an over-the-wire noncompliant balloon
catheter (Cook) or a high-pressure balloon catheter (Conquest
Balloon; Bard, Inc., Covington, GA, USA). After declotting of the
venous limb, the sheath was redirected into the arterial limb
for thromboaspiration and PTA. If an arterial plug was found, a
5F non-over-the-wire Fogarty thrombectomy balloon catheter
was used to dislodge the clot into the arterial limb. After the
restoration of a thrill in the access, a diagnostic ﬁstulogram
was obtained via digital subtraction analysis to inspect any
residual stenotic lesions and complications. If residual throm-
bus was detected beneath the sheath, the Fogarty balloon
catheter was used to dislodge the thrombus and re-establish
the ﬂow [7]. In the straight-conﬁguration AVG, a crossed-
catheter technique with dual access was applied and the
declotting process was performed in the same manner as
explained for the loop AVG thrombectomy. After sheath
removal, hemostasis was achieved with a modiﬁed purse-
string suture technique [8]. After a successful thrombectomy,
the dialysis access was immediately used for hemodialysis
treatment.
The declotting procedures for AVF thrombosis were per-
formed essentially the same way as those in AVG thrombec-
tomies. There was, however, a difference in the sheath
approach between the AVG and AVF thrombectomy proce-
dures. The approach for the AVG thrombectomy could be made
by using a relatively standard pattern, but the approach for the
AVF thrombectomy had to be individually applied according to
the characteristics of each AVF and the various causes of
thrombosis [9].
Hybrid technique
In particular cases, such as those with large volumes of hard
clots within a huge aneurysm, we also performed a hybrid
technique (surgical thrombectomy in combination with endo-
vascular angioplasty) [10]. A 2–3 cm transverse skin incision
was made over the dialysis access, followed by its dissection
from the surrounding tissue. After the vascular clamps were
located proximally and distally, a transverse venotomy was
made. Then the thrombus was removed with a 5F Fogarty
balloon catheter. The remaining thrombus was removed by
manual squeezing. A balloon angioplasty was performed for
the stenotic lesions using a noncompliant balloon catheter,
and a ﬁstulogram with digital subtraction analysis was
Table 1. Baseline characteristics
Characteristic Value
Number of patients 42
Number of percutaneous thrombectomies 75
Male/female 27:15 (64.3:35.7)
Patient age (y7SD) 64.5711.0
Dialysis access age (mo7SD) 39.5741.9
Number of procedures in diabetic patients 39 (52)
Location of dialysis access
Forearm 26 (34.7)
Upper arm 49 (65.3)
Type of AV ﬁstula
Radiocephalic 5 (62.5)
Brachiocephalic 3 (37.5)
Conﬁguration of AV graft
Loop 41 (61.2)
Straight 26 (38.8)
Location of AVG stenosisn
Arterial anastomosis 8 (11.9)
Venous anastomosis 49 (73.1)
Outﬂow vein 15 (22.4)
Central vein 9 (13.4)
Number of stenoses in a thrombosis case†
0‡ 4
1 45
2 24
3 2
n A thrombosed AV graft often had multiple stenoses at the same time.
† Overall, 94.7% of thrombosed access had signiﬁcant stenosis.
‡ In four cases of AVG thrombosis, signiﬁcant stenosis was not found.
AV, arteriovenous; AVG, arteriovenous graft; SD, standard deviation.
Table 2. Features of percutaneous thrombectomy
Method Success rate (%)
Crossed-catheter technique 39/45 (86.6)
Apex puncture technique in loop AVGn 20/22 (90.9)
Hybrid technique† 5/5 (100)
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the balloon angioplasty, the venotomy was closed by a micro-
surgical technique using 6–0 polypropylene sutures. All hybrid
technique procedures were successfully performed in the
angiography unit by an interventional nephrologist without
complications.
Deﬁnitions of outcome
According to the reporting standards from the SIR [4],
technical success was deﬁned as the restoration of ﬂow
combined with a residual stenosis of less than 30%, as based
on a good thrill. Clinical success was considered to have been
achieved when it functioned normally for at least one sub-
sequent hemodialysis session, in addition to the technical
success of the declotting procedure. The postinterventional
primary patency was deﬁned as the interval after the percu-
taneous thrombectomy until the next access thrombosis or any
subsequent access intervention. The postinterventional sec-
ondary patency was deﬁned as the interval after the percuta-
neous thrombectomy until the access was surgically declotted,
revised, or abandoned. Complications were classiﬁed as either
minor or major in accordance with the reporting standards of
the SIR [4].
Statistical analysis
The data are presented as mean7standard deviation or the
percentage. Kaplan–Meier survival analysis was performed to
analyze the primary and secondary patency rates after the
initial successful thrombectomy. For data analysis and pre-
sentation, the R project, version 3.1.0 (The R Foundation for
Statistical Computing, Vienna, Austria), was used. For the
analysis of patency, the datasets were censored in the cases
of patient death, transplantation, and loss of follow-up.Modiﬁed pharmacomechanical technique 3/3 (100)
Overall success rate 67/75 (89.3)
n Two cases of failure in apex puncture technique were attributable to
central vein occlusion and intervention withdrawn for surgical revision
of venous anastomotic stenosis, respectively.
† Hybrid technique was performed in three cases in AVF thrombosis and
two cases in AVG thrombosis.
AVF, arteriovenous ﬁstula; AVG, arteriovenous graft.Results
Baseline characteristics
From October 2010 to May 2014, 75 consecutive throm-
bectomy procedures were performed on 42 patients (27 men
and 15 women) with a mean age of 64.5711.0 years. Among
the 42 patients, 34 were diagnosed with AVG and 8 with AVF
thrombosis. The mean age of the dialysis access at the time of
thrombectomy was 39.5741.9 months (range, 3–223 months;
median, 30 months). The percutaneous thrombectomy cases in
AVG and AVF were 67 (89.3%) and eight (10.7%), respectively.
In the conﬁguration of AVG, the loop type accounted for 61.2%
(41/67) and the straight type accounted for 38.8% (26/67). The
baseline characteristics of percutaneous thrombectomies are
presented in Table 1.
Access survival rate
The clinical success rates of AVG and AVF thrombectomy
were 89.5% (60/67) and 87.5% (7/8), respectively. Among the
loop AVG thrombectomies, 53.7% (22/41) of the declotting
procedures were performed through the apex puncture tech-
nique, which was 90.9% (20/22) successful. In three cases,
mechanical thromboaspiration thrombectomy was performedwith a combination of a modiﬁed pharmacomechanical
thrombolysis technique [11].
There were seven technical failures during AVG thrombect-
omy, which were followed by surgical thrombectomy.
Table 2 summarizes the features of the percutaneous
thrombectomy procedures in this study.
For all successful thrombectomy cases, the postintervention
primary (unassisted) patency rates at 30 days, 90 days, and 180
days were 79.9% [95% conﬁdence interval (CI), 70.7–90.3%),
56.6% (95% CI, 45.4–70.5%), and 25.6% (95% CI, 16.0–41.0%),
respectively; the secondary patency rates at 30 days, 90 days,
and 180 days were 92.2% (95% CI, 85.8–99.0%), 85.7% (95% CI,
77.5–94.8), and 83.7% (95% CI, 74.8–93.5%), respectively. For
the successful cases of AVG thrombectomy, the postinterven-
tion primary (unassisted) patency rates at 30 days, 90 days,
and 180 days were 79.3% (95% CI, 69.5–90.4%), 58.8% (95% CI,
47.2–73.4%), and 28.8% (95% CI, 18.2–45.5%), respectively; the
secondary patency rates at 30 days, 90 days, and 180 days
were 93.0% (95% CI, 86.7–99.9%), 87.7% (95% CI, 79.5–96.7%),
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Meier survival curve of the postintervention primary and
secondary patency of the AVG thrombectomy is shown in
Fig. 1.Discussion
The KDOQI Vascular Access Guidelines emphasize that each
institution should monitor the outcome of treatment on the
basis of graft patency after percutaneous thrombectomy [3],
and recommend a clinical success rate of485%. In this study,
our overall clinical success rate was 89.3% (67/75), whereas the
clinical success rate of AVG thrombectomies was 89.5%
(60/67).
There were seven technical failures during AVG thrombect-
omy; the causes were as follows: failure to pass the guidewire
through a totally occluded central vein (2 cases); an incom-
plete removal of hard, adhesive clots within the large pseu-
doaneurysm (2 cases);430% residual stenosis owing to a
diffuse, thickened neointimal hyperplasia in the graft lumen
(1 case); and an intervention withdrawn by the operator’s
choice (2 cases). In the two withdrawn cases, a surgicalFigure 1. Kaplan–Meier survival curve for primary and secondary
patency of arteriovenous graft (AVG) thrombectomy.
Table 3. Comparison of the outcomes in arteriovenous graft thrombect
Authors Procedure number Device Techn
Sofocleous et al [18] 57 Amplatz
Trerotola et al [16] 64 Arrow-Trerotola
Lazzaro et al [19] 50 Arrow-Trerotola
Barth et al [20] 62 Oasis
Trerotola et al [16] 58 PSPMT
Littler et al [21] 20 Angiojet
Yang et al [22] 32 DHS
Goo et al [23] 225 DHS
Goo et al [17] 2,531 DHS
Present study 67 DHS
DHS, Desilets–Hoffman sheath; PSPMT, Pulse-spray pharmacomechanical ththrombectomy with revision was performed subsequently. In
the failed case of AVF thrombectomy, a technical success was
achieved, but the function of the AVF was inadequate for
subsequent hemodialysis treatment.
According to the KDOQI guidelines, the majority of reported
3-month primary (unassisted) patency rates range from 30% to
40% after percutaneous thrombectomy [12–16]. The Work
Group of KDOQI emphasized that percutaneous thrombectomy
should achieve a 3-month primary patency rate of440%. In
this study, the 90-day primary patency rates of the total cases
and of the AVG cases were 56.6% and 58.8%, respectively. These
outcomes exceed the recommended criteria of 40%, and are
comparable to the results of previously reported studies [17–
23] (Table 3).
There were no major complications that required hospita-
lization with surgical or medical treatment, and all of the
complications were treated successfully during the proce-
dures. There were two cases of minor vein dissection during
AVF thrombectomy and three cases of distal arterial emboliza-
tion during AVG thrombectomy. Distal arterial emboli were
percutaneously retrieved successfully during the procedure in
two cases, and observed in one other case, which had no
symptoms. Several months later, we performed a follow-up,
which showed normal arteriogram without emboli. Two cases
of minor vein dissection were also successfully treated by
prolonged intraluminal balloon inﬂation during the procedure.
Overall, the complication rate was 6.6% (5/75), and no cases of
procedure-related death were noted.
Although there are a variety of techniques that have been
introduced for mechanical thrombectomy, no clear advantage of
one technique over another has ever been documented [9]. In this
study, most of the thromboses were treated by a thromboaspira-
tion mechanical thrombectomy using a Desilets–Hoffman sheath.
For the declotting procedures of loop AVGs, we preferentially
performed an apex puncture technique, which may overcome
several of the disadvantages that result from the dual-access,
crossed-catheter approach for loop AVG [6]. The Fogarty balloon
application technique [7] was useful for compressing or displacing
any sheath entry point residual thrombus that did not wash away
spontaneously by arterial blood ﬂow. When a residual thrombus
was still present despite the use of a Fogarty balloon, it required
an additional sheath insertion to remove the sheath entry point
thrombus; we deﬁned these steps as dual access, cross-catheter
techniques and were hence excluded from the category of the
apex puncture technique. In cases of a straight-conﬁguration AVG,
the crossed-catheter technique was routinely performed because
the direction change of a single sheath was not favorable.omy
ical success (%) Complications (%) Primary patency rate (%)
30 d 90 d
93 16 65 50
95 11 39 20
100 14 42
95 11 69 40
95 22 40 25
95 12 80 57
75 12.5 81
88.9 17.8 63.1
96 12 76 62
89.5 6.6 79.3 58.8
rombolysis.
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venous anastomosis in the lesion refractory to PTA, and stents
were used in 2.56% of the percutaneous thrombectomy pro-
cedures in this study. Stents are used sparingly in our center
for cases of PTA-induced venous rupture or elastic recoil of
stenosis with no surgical option, in accordance with KDOQI
Vascular Access Guidelines [3].
All patients with dialysis access thrombosis that visited our
center were imaged with Doppler ultrasonography prior to the
declotting procedure, thus allowing for the selection of the
more favorable method (percutaneous thrombectomy or sur-
gical thrombectomy). During the preprocedural ultrasono-
graphic examinations of AVF thrombosis, a large majority
exhibited distinct causative lesions that tended to require
surgical modiﬁcations in addition to the thrombectomy, and
many cases of AVF thrombosis were treated via surgical
thrombectomy by a vascular surgeon. It was common that an
AVF thrombosis due to a juxta-anastomotic stenosis with
calciﬁed plaques was treated by proximal reanastomosis with
surgical thrombectomy. This tendency of AVF thrombosis
explains why cases of percutaneous thrombectomy in AVF
thrombosis are relatively fewer than those of AVG thrombect-
omy in this study.
Here, we have focused on thrombectomies, not on entire
endovascular procedures. The patency of a dialysis access after
mechanical thrombectomy depends on the result of treatment
for underlying stenoses [24,25], and clot removal is only a part
of the procedure. An underlying stenosis is frequently (4 85%)
the cause of AVG thrombosis [15,16], so a high success rate and
longer patency include a successful angioplasty during the
thrombectomy procedure. In addition, thrombectomy proce-
dures are not elective but urgent. Most thrombosis episodes
are found on the day of the hemodialysis treatment, especially
for AVG. Therefore, emergency percutaneous thrombectomy is
frequently required to have the hemodialysis treatment as
scheduled. According to the European Best Practice Guidelines
on Vascular Access, dialysis access thrombosis should be
treated without unnecessary delay and within 48 hours, prior
to the next dialysis session [2], and KDOQI guidelines recom-
mend that thrombectomy procedures be performed as soon as
possible to avoid the need for a central venous catheter [3].
Therefore, an evaluation of the outcomes of percutaneous
thrombectomy procedures represents how well qualiﬁed the
center is in performing emergency thrombectomies. In this
study, all percutaneous thrombectomies were performed
within 24 hours of diagnosis. There were no cases where
hemodialysis treatment were not undertaken as scheduled,
nor were central venous dialysis catheters needed, except in
the cases of clinically failed percutaneous thrombectomy
followed by a subsequent surgical thrombectomy.
This result indicates that if the nephrologists were actively
involved in performing immediate diagnostic and therapeutic
interventions, unnecessary delays in declotting procedures
could be avoided by reducing the waiting time caused by
referring patients between multiple departments.
Because nephrologists are typically the ﬁrst doctor to notice
a thrombosis event and the closest physician who can monitor
vascular access for extended periods in the hemodialysis
center, it would be ideal for the patients for the nephrologist
to perform the salvage procedures for a clotted dialysis access.
Owing to their unique perspectives on the hemodialysis
treatment and hemodynamics of vascular access, these spe-
cialists are ideally suited to perform this activity. Indeed,recent data have emphasized that nephrologists can safely
and successfully perform these procedures with excellent
results [9]. Likewise, the outcome of this study satisﬁed the
recommendations of the KDOQI guidelines, and was compar-
able to other reports. Percutaneous thrombectomy performed
by an interventional nephrologist was safe and effective, and
this result was in accordance with current trends indicating
that endovascular treatment by interventional nephrologists
has become more popular worldwide.Conﬂict of interest
None.
References
[1] Current Renal Replacement Therapy in Korea, 2013. Available at:
http://www.ksn.or.kr/journal/2014/index.html [Date accessed: 28
July 2014]
[2] Tordoir J, Canaud B, Haage P, Konner K, Basci A, Fouque D,
Kooman J, Martin-Malo A, Pedrini L, Pizzarelli F, Tattersall J,
Vennegoor M, Wanner C, ter Wee P, Vanholder R: EBPG on
vascular access. Nephrol Dial Transplant 22:ii88–ii117, 2007
[3] National Kidney Foundation: K/DOQI clinical practice guidelines
for vascular access. Am J Kidney Dis 48:S176–S276, 2006
[4] Gray RJ, Sacks D, Martin LG, Trerotola SO: Reporting standards for
percutaneous interventions in dialysis access. J Vasc Interv Radiol
14:S433–S442, 2003
[5] Trerotola SO, Lund GB, Scheel Jr PJ, Savader SJ, Venbrux AC,
Osterman Jr FA: Thrombosed dialysis access grafts: percutaneous
mechanical declotting without urokinase. Radiology 191:721–726,
1994
[6] Hathaway PB, Vesely TM: The apex-puncture technique for
mechanical thrombolysis of loop hemodialysis grafts. J Vasc Interv
Radiol 10:775–779, 1999
[7] Goo DE, Yang SB, Kim YJ, Moon C, Song D, Yoon SC, Lee WH:
Fogarty balloon application technique in dislodging residual
thrombus on the single sheath entry point at the apex of
thrombosed loop grafts. Diagn Interv Radiol 19:150–153, 2013
[8] Simons ME, Clark TWI, Rajan DK: The woggle technique: a new
method of suture closure of hemodialysis arteriovenous grafts
and ﬁstulas after percutaneous interventions. J Vasc Interv Radiol
12:S30, 2001. ([Abstract])
[9] Beathard GA, Litchﬁeld T, Physician Operators Forum of RMS
Lifeline, Inc. Effectiveness and safety of dialysis vascular access
procedures performed by interventional nephrologists. Kidney Int
66:1622–1632, 2004
[10] Hyun JH, Lee JH, Park SI: Hybrid surgery versus percutaneous
mechanical thrombectomy for the thrombosed hemodialysis
autogenous arteriovenous ﬁstulas. J Korean Surg Soc 81:43–49,
2011
[11] Choi SY, Choi BG, Han KH, Chun HJ: Efﬁcacy of a modiﬁed
pharmacomechanical thrombolysis technique for endovascular
treatment of thrombosed prosthetic arteriovenous grafts. Korean
J Radiol 13:300–306, 2012
[12] Falk A, Guller J, Nowakowski FS, Mitty H, Teodorescu V, Uribarri J,
Vassalotti J: Reteplase in the treatment of thrombosed hemodia-
lysis grafts. J Vasc Interv Radiol 12:1257–1262, 2001
[13] Sofocleous CT, Hinrichs CR, Weiss SH, Contractor D, Barone A,
Bahramipour P, Brountzos E, Kelekis D: Alteplase for hemodialysis
access graft thrombolysis. J Vasc Interv Radiol 13:775–784, 2002
[14] Vogel PM, Bansal V, Marshall MW: Thrombosed hemodialysis
grafts: lyse and wait with tissue plasminogen activator or uroki-
nase compared to mechanical thrombolysis with the Arrow-
Trerotola percutaneous thrombolytic device. J Vasc Interv Radiol
12:1157–1165, 2001
Lee and Park / Percutaneous thrombectomy 209[15] Cohen MA, Kumpe DA, Durham JD, Zwerdlinger SC: Improved
treatment of thrombosed hemodialysis access sites with throm-
bolysis and angioplasty. Kidney Int 46:1375–1380, 1994
[16] Trerotola SO, Vesely TM, Lund GB, Soulen MC, Ehrman KO,
Cardella JF: Treatment of thrombosed hemodialysis access grafts:
Arrow-Trerotola percutaneous thrombolytic device versus pulse-
spray thrombolysis. Arrow-Trerotola Percutaneous Thrombolytic
Device Clinical Trial. Radiology 206:403–414, 1998
[17] Goo DE, Kim YJ, Park ST, Yang SB, Yoon SC, Song D: Thromboas-
piration of arteriovenous hemodialysis graft thrombosis using
Desilets-Hoffman sheath: single-center experience. J Vasc Access
2014. Available at: http://www.vascular-access.info/article/throm
boaspiration-of-arteriovenous-hemodialysis-graft-thrombosis-u
sing-desilets-hoffman-sheath–single-center-experience [Date
accessed: 28 July 2014]
[18] Sofocleous CT, Cooper SG, Schur I, Patel RI, Iqbal A, Walker S:
Retrospective comparison of the Amplatz thrombectomy device
with modiﬁed pulse-spray pharmacomechanical thrombolysis in
the treatment of thrombosed hemodialysis access grafts. Radiol-
ogy 213:561–567, 1999
[19] Lazzaro CR, Trerotola SO, Shah H, Namyslowski J, Moresco K, Patel
N: Modiﬁed use of the arrow-trerotola percutaneous thrombolyticdevice for the treatment of thrombosed hemodialysis access
grafts. J Vasc Interv Radiol 10:1025–1031, 1999
[20] Barth KH, Gosnell MR, Palestrant AM, Martin LG, Siegel JB,
Matalon TA, Goodwin SC, Neese PA, Swan TL, Uﬂacker R: Hydro-
dynamic thrombectomy system versus pulse-spray thrombolysis
for thrombosed hemodialysis grafts: a multicenter prospective
randomized comparison. Radiology 217:678–684, 2000
[21] Littler P, Cullen N, Gould D, Bakran A, Powell S: AngioJet
thrombectomy for occluded dialysis ﬁstulae: outcome data. Car-
diovasc Intervent Radiol 32:265–270, 2009
[22] Yang SB, Goo DE, Kim DH, Lee HK, Choi DL, Kwon KH, Hong HS,
Moon C: Percutaneous mechanical declotting of thrombosed
dialysis graft. J Korean Radiol Soc 43:411–416, 2000
[23] Goo DE, Kim JH, Park ST, Chang YW, Hwang JH, Kwon KH, Choi DL,
Mun C: Usefulness of thromboaspiration with Desilets–Hoffman
sheath in thrombosed hemodialysis access graft. J Korean Radiol
Soc 51:45–53, 2004
[24] Beathard GA: Percutaneous transvenous angioplasty in the treat-
ment of vascular access stenosis. Kidney Int 42:1390–1397, 1992
[25] Kanterman RY, Vesely TM, Pilgram TK, Guy BW, Windus DW,
Picus D: Dialysis access grafts: anatomic location of venous
stenosis and results of angioplasty. Radiology 195:135–139, 1995
